You are about to access information on our medicines and medical devices aimed exclusively at healthcare professionals.

By virtue of Spanish Royal Decree 1416/1994 of 25 June regulating the advertising of medicinal products for human use, Spanish Royal Decree 1591/2009 of 16 October regulating medical devices and Law 29/2006 of 26 July on the guarantees and rational use of medicines and health products, in this section Bioibérica can only offer advertising content of prescription medicines to health personnel authorised to prescribe or dispense them.

I am a health professional authorised to prescribe or dispense, or a pharma company professional.

  1. Home
  2. Products
  3. Portfolio
  4. Hialsorb® Intraarticular

Hialsorb® Intraarticular

Temporary substitute for synovial fluid for patients affected by degenerative or mechanical joint diseases that cause pain or reduced mobility.

Hialsorb® Intraarticular complies with the regulations of medical devices.

Information updated January 2019.

Composition and dose

Hialsorb® Intraarticular contains hyaluronic acid sodium salt as an active substance, and is presented in a syringe that contains 3 mL of transparent, sterile, non-pyrogenic viscoelastic solution of hyaluronic acid at 2% (20mg/ml).

This hyaluronic acid is chemically obtained by biofermentation with no modifications (non-crosslinked), and has a molecular weight of 1,000 – 1,200 kDa.

The recommended dose is a single injection per treatment cycle. The physician in charge will assess the possibility of administering another dose based on the patient's status.

Hialsorb® Intraarticular is a medical device which is not financed by Social Security, registered in Spain by the Spanish Agency of Medicines and Medical Devices (AEMPS).

It is also marketed in other countries. Please contact us for more information.

IMPORTANT: this product must be administered exclusively by a physician.

Efficacy and safety

The medical literature shows that hyaluronic acid injections exert a viscosupplementary effect1-3 (it restores the viscosity and elasticity of synovial fluid), which decreases the friction within the joint and also has a pharmacological effect, with a subsequent reduction in pain, and an improvement in mobility, without exerting any systemic action1-4.

Concerning safety, Hialsorb® Intraarticular is better tolerated than other hyaluronic acids, since it is not crosslinked and due to its lower molecular weight5.


1. Goldberg VM, et al. Pain Res. 2010 May 10;3:51-6.

2. Maheu E, et al. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S28-33.

3. Altman RD, et al. BMC Musculoskelet Disord. 2015 Oct 26;16:321.

4. du Souich, P. Pharmacol Ther. 2014 Jun;142(3):362-74

5. Hamburger MI, et al. Semin Arthritis Rheum. 2003 Apr;32(5):296-309.

To consult these studies, apart from the additional bibliography and other relevant contents on osteoarthritis, you can visit


Hialsorb® Intraarticular is not financed by Social Security.

If you are a professional, please contact our commercial department using the form below.